Donoghue Forlines’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,323
| Closed | -$1.56M | – | 275 |
|
|
2024
Q2 | $1.56M | Sell |
3,323
-434
| -12% | -$203K | 0.44% | 49 |
|
|
2024
Q1 | $1.57M | Buy |
3,757
+2,357
| +168% | +$985K | 0.45% | 68 |
|
|
2023
Q4 | $570K | Sell |
1,400
-3,896
| -74% | -$1.59M | 0.18% | 151 |
|
|
2023
Q3 | $1.84M | Sell |
5,296
-169
| -3% | -$58.8K | 0.66% | 25 |
|
|
2023
Q2 | $1.92M | Sell |
5,465
-94
| -2% | -$33.1K | 0.6% | 25 |
|
|
2023
Q1 | $1.75M | Buy |
5,559
+74
| +1% | +$23.3K | 0.63% | 24 |
|
|
2022
Q4 | $1.58M | Buy |
5,485
+1,517
| +38% | +$438K | 0.56% | 36 |
|
|
2022
Q3 | $1.15M | Buy |
3,968
+213
| +6% | +$61.7K | 0.41% | 24 |
|
|
2022
Q2 | $1.06M | Buy |
3,755
+527
| +16% | +$148K | 0.28% | 83 |
|
|
2022
Q1 | $842K | Buy |
+3,228
| New | +$842K | 0.18% | 179 |
|
|
2021
Q3 | – | Sell |
-5,151
| Closed | -$1.04M | – | 245 |
|
|
2021
Q2 | $1.04M | Buy |
5,151
+345
| +7% | +$69.6K | 0.19% | 133 |
|
|
2021
Q1 | $1.03M | Buy |
4,806
+11
| +0.2% | +$2.36K | 0.2% | 129 |
|
|
2020
Q4 | $1.13M | Buy |
+4,795
| New | +$1.13M | 0.22% | 117 |
|